• 1.

    Garrelfs SF, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 2021; 384:12161226. doi: 10.1056/NEJMoa2021712

Lumasiran Offers a New, Effective Treatment for Primary Hyperoxaluria Type 1 (PH1)

  • 1 Stephanie Perez Kerkvliet, MD, is a Pediatrics Resident Physician, and Michelle N. Rheault, MD, is Director, Division of Pediatric Nephrology, and Associate Professor of Pediatrics, University of Minnesota Masonic Children's Hospital, in Minneapolis.
Restricted access
Save